Skip to main content


Scientific Name(s): Trigonella foenum-graecum L.
Common Name(s): Faenum graecum, Fenugreek, Huluba, Methi, Semen Trigonellae

Medically reviewed by Last updated on Aug 14, 2023.

Clinical Overview


Limited clinical trial data suggest fenugreek extracts may have a role in the therapy of dyslipidemia, diabetes, and Parkinson disease; however, studies were limited and provided inconsistent dosing information, making it difficult to provide recommendations. Anti-inflammatory, antioxidant, and cytotoxic properties have yet to be fully explored.


Wide-ranging dosages and differing preparations have been used in clinical studies. A standardized hydroalcoholic extract of fenugreek seeds is available, and a trial evaluated its use in patients with Parkinson disease at 300 mg twice daily for a period of 6 months. Studies in patients with type 2 diabetes and hypercholesterolemia have used from 1 g/day of a hydroalcoholic extract of fenugreek up to 100 g/day of germinated fenugreek seeds, whereas seed powder 1.8 to 2.7 g taken 3 times daily for the first 3 days of menstruation was used in primary dysmenorrhea (total daily dose, 5.4 to 8.1 g); 500 mg twice daily of a standardized extract was studied for management of postmenopausal symptoms.


Contraindications have not yet been identified. Avoid if an allergy to any member of the Fabaceae family exists. Cross-reactivity to chickpea, peanut, or coriander allergy is possible.


Avoid use in pregnancy. Fenugreek has been documented to have uterine stimulant effects and has been used in traditional medicine to induce childbirth. Animal studies have demonstrated abortifacient effects in females and antifertility effects in males and females; whereas congenital malformations have been observed in humans as well as animals. Fenugreek has been used to stimulate milk production in breast-feeding mothers, but data are insufficient to determine its efficacy and safety, and the extent of transmission of fenugreek-derived constituents into breast milk is unknown.


Interactions with anticoagulant and hypoglycemic agents are possible; monitor therapy.

Adverse Reactions

Mild and transient GI effects are most commonly reported; hypoglycemia, micturition, dizziness have also been documented within a range of doses and variety of preparations. When ingested in culinary quantities, fenugreek is usually devoid of adverse reactions. Allergy to fenugreek is recognized, including severe responses such as asthma, anaphylaxis, and toxic epidermal necrosis. Cross-reactivity to legumes is possible; consider allergy potential with chickpea, peanuts, soybeans, lentils, lupin, green peas, or coriander.


To prevent accidental overdose, oral doses for humans should not exceed 350 mg/kg (21 g/60 kg).

Scientific Family

  • Fabaceae (bean)


A member of the bean family, fenugreek grows as an erect annual with long, slender stems reaching 30 to 60 cm tall. The plant bears grey-green, tripartite, toothed leaves, and white or pale yellow flowers appear in summer and develop into long, slender, sword-shaped seed pods with a curved, beaklike tip. Each pod contains about 10 to 20 small, yellowish-brown, angular seeds, which are dried to form the commercial spice. The plant thrives in full sun and in rich, well-drained soils, and has a spicy odor that remains on the hands after contact.1, 2


Fenugreek herb has been used for centuries as a cooking spice in Europe and remains a popular ingredient in pickles, curry powders, and spice mixtures in India and other parts of Asia. In folk medicine, fenugreek has been used to treat boils, cellulitis, and tuberculosis. It was a key ingredient in a 19th century patent medicine Lydia Pinkham's Vegetable Compound, which was used for dysmenorrhea and postmenopausal symptoms. It has also has been recommended for the promotion of lactation. Fenugreek seeds have been used as an oral insulin substitute, and seed extracts have been reported to lower blood glucose levels. The maple aroma and flavor of fenugreek has led to its use in imitation maple syrup. The seeds are rich in protein, and the plant is grown as animal forage. Diosgenin, a precursor used in commercial steroid synthesis, is extracted from the seeds. The remaining residue is rich in nitrogen and potassium, and is used as an agricultural fertilizer.2, 3


The leaves contain at least 7 saponins, known as graecunins, which are glycosides of diosgenin. Seeds contain 0.1% to 0.9% diosgenin and are extracted on a commercial basis. Plant tissue cultures from seeds grown under optimal conditions have been found to produce as much as 2% diosgenin with smaller amounts of gitongenin and trigogenin. The seeds also contain the saponin fenugrin B. Several coumarin compounds have been identified in fenugreek seeds, as well as a number of alkaloids (eg, trigonelline, gentianine, carpaine), including the alkaloid hydroxyisoleucine, which is considered to stimulate insulin secretion. During roasting, a large proportion of the trigonelline is degraded to nicotinic acid and related pyridines. These degradation products are, in part, responsible for the flavor of the seed. The seeds also yield as much as 8% of a fixed, foul-smelling oil. Standardization of seed content has been reported on.4, 5, 6, 7, 8

The C-glycoside flavones vitexin, vitexin glycoside, and the arabinoside isoorientin have been isolated from the plant. Three minor steroidal sapogenins, smilagenin, sarsasapogenin, and yuccagenin, also have been found in the seeds.9, 10 The lactone sotolone is responsible for the plant's characteristic smell.

The mucilages of fenugreek's and several other plants' seeds have been determined and their hydrolysates analyzed.11 Fenugreek gel consists chiefly of galactomannans, characterized by their high water-holding capacity. These galactomannans have a unique structure and may be responsible for some of the characteristic therapeutic properties attributed to fenugreek.3

Uses and Pharmacology

The use of fenugreek has been limited by its bitter taste and pungent odor. Isolation of the biologically active components or production of a more palatable extract, which would allow greater use of the plant, have been investigated.3

Anti-inflammatory effects

Animal data

Suppression of interleukin production and allergic symptoms were demonstrated in rats pretreated with fenugreek extracts.12, 13, 14 Inhibition of the arachidonic acid pathway was demonstrated in mice,15 and studies in rats with induced arthritis have found positive effects on erythrocyte sedimentation rate, total white blood cells, and C-reactive protein.14, 16

Clinical data

There are very limited clinical data regarding the use of fenugreek as an anti-inflammatory agent. A Cochrane systematic review and meta-analysis of dietary supplements for dysmenorrhea identified only low or very low quality studies with very small sample sizes. Very limited evidence of effectiveness was found for the treatment of primary dysmenorrhea with fenugreek compared to placebo or no treatment (1 randomized clinical trial, N = 101). Fenugreek seed powder dosage was 1.8 to 2.7 g taken 3 times daily for the first 3 days of menstruation (total daily dose, 5.4 to 8.1 g). No side effects were observed.84

Antioxidant effects

High levels of polyphenolic flavonoids (more than 100 mg per 100 g) have been isolated from fenugreek seeds.17 These were associated with dose-dependent protection of erythrocytes from antioxidant damage in an in vitro study.18

Animal data

Models of toxicity in laboratory studies (including cardio-, hepato-, nephro-, and neurotoxicity) have shown that fenugreek exerts antioxidant protective effects.19, 20, 21, 22, 23

Clinical data

There are no clinical data regarding the use of fenugreek as an antioxidant.


Animal data

In vitro studies with human cancer cell lines and experiments in laboratory animals have shown that fenugreek and certain constituents, especially diosgenin, exert growth inhibitory and cytotoxic effects. Studies have included T lymphoma cells, squamous cell, breast, pancreatic, and prostate cancer, among others.24, 25, 26, 27, 28, 29, 75

Clinical data

There are no clinical data regarding the use of fenugreek as an antitumor agent.

CNS effects

Animal data

In a screening study, fenugreek exhibited activity in a monoamine oxidase type A assay but did not demonstrate affinity for the serotonin transporter.30 In a model of sciatic nerve injury in rats, an extract of fenugreek restored motor nerve conduction but not nerve ligation.31 In a model of Parkinson disease in rats, fenugreek seed extract demonstrated neuroprotective effects and reversed motor-related symptoms.32

Clinical data

A small clinical study evaluated the effect of adjuvant standardized hydroalcoholic extract of fenugreek seeds in patients with Parkinson disease. Outcome measures included the Unified Parkinson's Disease Rating Scale (UPDRS), and Hoehm and Yahr (H & Y) staging measured at baseline and at 6 months. Fenugreek showed greater efficacy than placebo, but further, larger trials are required to determine if fenugreek has a place in the treatment of Parkinson disease.33 A double-blind, placebo-controlled trial found clinically significant beneficial changes in total and motor UPDRS scores as well as H & Y staging for 42 early Parkinson patients taking 300 mg twice daily of a standardized fenugreek extract for 6 months as a nutritional adjuvant to levodopa/carbidopa therapy.82


The galactomannan-rich soluble fiber fraction of fenugreek may be responsible for the antidiabetic activity of the seeds.3 Insulinotropic and antidiabetic properties also have been associated with the amino acid 4-hydroxyisoleucine, which occurs in fenugreek at a concentration of about 0.55%. In vitro studies have indicated that this amino acid directly stimulates pancreatic beta-cells. Delayed gastric emptying and inhibition of glucose transport have also been postulated as possible mechanisms, as well as restoration of enzymes involved in glycolysis and gluconeogenesis.8, 34 Hypoglycemic effect appears greatest for fenugreek whole seed powder, with lesser effect for the gum isolate, other seed extracts, and leaves.35

Animal data

Reports of experiments in animals from the 1980s and 1990s have been published,35, 36 and studies to elucidate the mechanisms of action of fenugreek in diabetes are ongoing.37, 38, 39, 40, 41, 42

Clinical data

A lack of standardization of products tested and dosages used limits the value of the limited published clinical trials. One small clinical study was conducted among patients with type 1 diabetes, and the balance was conducted among healthy participants or those with type 2 diabetes.8, 36 Most studies found a reduction of fasting blood glucose of 30 to 45 mg/dL,8, 43 and some showed a decrease in glycosylated hemoglobin. Only 1 study out of 7 showed an effect on insulin.44 Study methodology limitations exist. A clinical trial evaluated the effects of fenugreek fiber 4 and 8 g at breakfast in adult non-diabetic patients with a body mass index of 30 or higher. Both fenugreek fiber doses significantly lowered patient-rated hunger and calories consumed at the next meal, and the higher dose produced a significant increase in insulin area under the curve. Neither dose produced a significant reduction in postprandial blood glucose.76

A systematic review and meta-analysis identified 10 clinical trials that evaluated the effect of fenugreek intake on glucose homeostasis markers including fasting blood glucose, 2-hour postload glucose, HbA1c, and fasting serum insulin levels. Sample sizes ranged from 5 to 69 and most trials included patients with type 2 diabetes. Fenugreek seed daily doses ranged from 1 to 100 g (median, 25 g) given over a range of 10 to 84 days (median, 30 days). In all 10 studies, significant effects were observed on fasting blood glucose (FBG) compared with controls (P < 0.001) in patients with diabetes (types 1 and 2) but not in participants without diabetes; doses less than 5 g/day were unlikely to produce effects. Additionally, the 2-hour glucose pooled estimate from 7 trials was significant (P < 0.001). HbA1c was also significantly reduced compared with controls (P = 0.009); however, fasting serum insulin levels were not significantly different. Heterogeneity was significant for fasting blood glucose and 2-hour postload but not for HbA1c or fasting insulin serum results.83 Similar results were found with pooled data for FBG (−0.84 mmol/L; P=0.002), HbA1c (−1.16; P<0.00001), and 2-hour postprandial blood glucose (−1.3 mmol/L; P<0.001) in patients with diabetes or pre-diabetes compared to controls in a 2016 meta-analysis of 12 studies (N=1,173). Heterogeneity observed with FBG was deemed likely due to diseases. Additionally, effects of fenugreek on lipid parameters were assessed and the pooled data revealed a significant decrease with fenugreek on triglycerides (−0.27 mmol/L; P=0.01) and total cholesterol (−0.30 mmol/L; P=0.03). No significant effects were found on low-density lipoprotein or high-density lipoprotein levels overall. The availability of only 1 study for pre-diabetes limited the usefulness of disease subgroup analysis. Transient and mild GI effects were the most commonly reported side effects in fenugreek groups; however, comparisons could not be drawn with hypoglycemic agents due to a lack of data on the latter. Fenugreek doses ranged from 1 to 100 g (median, 6.3 g) given as a capsule or powder for 1 week to 3 years (median, 60 days). Duration of therapy did not appear to reduce efficacy or induce resistance. The quality of the majority of studies was low with only 3 being scored as high quality.89


Fecal bile acid and cholesterol excretion are increased by fenugreek administration.3 This may be secondary to a reaction between the bile acids and fenugreek-derived saponins causing the formation of micelles too large for the digestive tract to absorb. Another hypothesis attributes the cholesterol-lowering activities to the fiber-rich gum portion of the seed, which reduces the rate of hepatic synthesis of cholesterol. It is likely that both mechanisms contribute to the overall effect.

Animal data

Studies have demonstrated the cholesterol-lowering activity of fenugreek in animals, including rats and dogs.17, 35, 36, 40, 45, 46

Clinical data

A systematic review identified 5 clinical trials before 2003 that investigated the cholesterol-lowering effects of fenugreek seeds. Reductions of serum cholesterol (15% to 33%) from baseline were reported in all the trials identified.47 Results from further studies conducted among patients with diabetes found equivocal results, with most reporting decreases in total cholesterol, triglycerides, and low-density lipoprotein.8, 34, 89

Other uses


Antifungal and antibacterial properties have been demonstrated.17 A French patent was granted to a product containing extracts of several herbal products, including fenugreek, purported to have activity against human and animal flagellate parasites.48


Oral administration of fenugreek seed fractions and fiber products resulted in dose-dependent gastric protection similar to that of nonprescription antacid medication.17, 49, 50, 77 Because of the association of Helicobacter pylori with gastritis, peptic ulcer, and gastric cancer, in vitro experimentation was conducted in H. pylori-infected gastric epithelial cells with 24 medicinal plants indigenous to Pakistan to evaluate their effect on secretion of IL-8 and generation of reactive oxygen species (ROS) in order to assess anti-inflammatory and cytoprotective effects. Although no significant direct cytotoxic effects on the gastric cells or bactericidal effects on H. pylori were found, fenugreek was observed to have mild and moderate inhibitory activity on IL-8 at 50 and 100 mcg/mL, respectively, in H. pylori-infected gastric cells.85


Reduction in cataract incidence was demonstrated in diabetic rats receiving an extract of fenugreek seeds and leaves. After 115 days of treatment, cataracts were diagnosed in 25% of fenugreek recipients compared with 100% of diabetic controls.51


The effects of a proprietary fenugreek seed husk extract (FenuSMART) was assessed in symptomatic menopausal women in a double-blind, randomized, placebo-controlled trial (n = 88). The primary inclusion criterion was last menses between 12 months and 3 years; although, the authors noted ambiguously that the last menstrual period in participants of both groups was noted to have occurred before 12 months. Fenugreek extract 500 mg/day (250 mg twice daily) was administered for 1 week followed by 1,000 mg/day (500 mg twice daily) for 12 weeks. At the end of the study period, mean total menopausal symptom scores were significantly lower in the extract-treated group (−15.19) compared to placebo (−3.71; P <0.001), as well as compared to baseline. Each of the 8 individual climacteric subscale scores was also significantly improved with the fenugreek extract (P < 0.01). No adverse effects were reported or observed with fenugreek extract.87


Wide-ranging dosages and differing preparations have been used in clinical studies.

Studies in patients with type 2 diabetes and hypercholesterolemia have used 5 g/day of seeds or 1 g/day of a hydroalcoholic extract of fenugreek.34

A trial in patients with Parkinson disease evaluated the safety of a standardized hydroalcoholic extract of fenugreek seeds at a dosage of 300 mg twice daily over 6 months.33

Fenugreek seed powder 1.8 to 2.7 g taken 3 times daily for the first 3 days of menstruation was used in primary dysmenorrhea (total daily dose, 5.4 to 8.1 g).84

Pregnancy / Lactation

Avoid use in pregnancy. Fenugreek has documented uterine stimulant effects and has been used in traditional medicine to induce childbirth and hasten delivery by promoting uterine contractions. Studies in pregnant mice and rats have shown intrauterine growth retardation, fetal malformations, and increased fetal mortality related to fenugreek seed consumption and various other preparations (ie, crude non-polar steroidal fraction of fenugreek seed, fenugreek alcohol extract, fenugreek seed powder, saponin extract, decoction from fenugreek leaves). Animal studies have also demonstrated antifertility effects in both males and females. Anti-implantation and abortifacient effects have been demonstrated in female rodents and rabbits, whereas reduced sperm counts and motility, genetic damage in germ cells, and toxic effects on testicular tissue were seen in male animals. These effects were observed at a dose as low as 100 mg/kg/day, a human dose equivalent of 16.2 mg/kg (972 mg/60 kg).17, 52, 90 In humans, congenital malformations (ie, hydrocephalus, anencephaly, cleft palate, spina bifida) have been reported in offspring of women who consumed fenugreek seeds during pregnancy.90

Maple syrup urine disease, a disorder of branched-chain amino acid catabolism that results in abnormal accumulations of amino acids and their metabolites, was suspected in a healthy infant born to a mother who ingested a paste prepared from fenugreek seeds early in labor.53 Fenugreek, maple syrup, and the urine of patients with the disease share a characteristic odor originating from the common constituent sotolone.

Fenugreek is a widely used herbal agent, but data are insufficient to determine its efficacy and safety. It is not known whether components of the herb are transferred to the infant via breast milk. Fenugreek seeds have been used in traditional medicine to augment breast milk supply.54, 92 State-wide surveys in California, Texas, and North Carolina identified fenugreek as one of the 4 most common herbs used by certified or licensed midwives for increasing lactation.93 Fenugreek has been shown to stimulate sweat production, offering a possible mechanism of action. A study conducted in 2011 evaluated the efficacy of fenugreek as a galactogogue; however, the extent of transmission of fenugreek-derived constituents into breast milk is unknown and efficacy has yet to be established.55 Compared to placebo and other galactogogues in a network meta-analysis (N=242; range, 22 to 122), fenugreek produced significantly more breast milk than placebo but not Coleus amboinicus or palm dates. Doses were varied and, at times, it was unclear if taken as fenugreek tea (seed powder) or seed-filled capsules for durations of 21 to 244 days.92


Agents with antiplatelet properties: Herbs (anticoagulant/antiplatelet properties) may enhance the adverse/toxic effect of agents with antiplatelet properties. Bleeding may occur. Consider therapy modification.(56, 57, 58, 59)

Anticoagulants: Herbs (anticoagulant/antiplatelet properties) may enhance the adverse/toxic effect of anticoagulants. Bleeding may occur. Consider therapy modification.(56, 57, 58, 59, 78)

Herbs (anticoagulant/antiplatelet properties): May enhance the adverse/toxic effect of other herbs (anticoagulant/antiplatelet properties). Bleeding may occur. Consider therapy modification.(56, 57, 58, 59)

Hypoglycemic agents: Herbs (hypoglycemic properties) may enhance the hypoglycemic effect of hypoglycemic agents. Monitor therapy.(60)

Nonsteroidal anti-inflammatory agents: Herbs (anticoagulant/antiplatelet properties) may enhance the adverse/toxic effect of nonsteroidal anti-inflammatory agents. Bleeding may occur. Consider therapy modification.(56, 57, 58, 59)

Salicylates: Herbs (anticoagulant/antiplatelet properties) may enhance the adverse/toxic effect of salicylates. Bleeding may occur. Consider therapy modification.(56, 57, 58, 59)

Sertraline: Fenugreek may enhance the serotonergic effect of sertraline. This could result in serotonin syndrome. Monitor therapy.(94)

Thrombolytic agents: Herbs (anticoagulant/antiplatelet properties) may enhance the adverse/toxic effect of thrombolytic agents. Bleeding may occur. Consider therapy modification.(56, 57, 58, 59)

Vitamin K antagonists: Fenugreek may enhance the anticoagulant effect of vitamin K antagonists. Monitor therapy.(61, 62, 63, 78)

Warfarin: Fenugreek may enhance the anticoagulant effect of warfarin. Monitor therapy.(61, 62, 63)

Adverse Reactions

Fenugreek is generally recognized as safe for use both as a spice and as a fiber. When ingested in culinary quantities, fenugreek is usually devoid of adverse reactions.64 Mild transient GI effects (ie, dyspepsia, abdominal distention, diarrhea, flatulence, nausea) have been reported with chronic administration in diabetic patients as well as healthy adults in clinical studies and case reports with dosages ranging from 1 mg/day hydro-alcoholic seed extract for 2 months to 12.5 g fenugreek seed powder given twice daily for up to 24 weeks.2, 65, 90 Uncompensated coagulation failure in a patient with cirrhosis was believed to be attributed to coumarins from long-term, high doses of fenugreek-based porridge.91

Hypoglycemia has been reported in diabetic and healthy adults given 100 g of defatted fenugreek seed powder for as little as 10 days. In another study, micturition and dizziness were reported within 24 hours of acute administration of a 40 mg/kg single dose of aqueous leaf extract.90 A trial evaluating the safety of a standardized hydroalcoholic extract of fenugreek seeds at a dosage of 300 mg twice daily over 6 months reported no hematological or biochemical effects, including effects on liver and kidney function tests, over placebo.33 In contrast, animal studies have repeatedly documented histopathological and hematological changes in the liver and kidney.90

Fenugreek should be used with caution in individuals taking thyroid hormones because animal studies suggest that it may alter T3 and T4 levels.66, 67

Allergy to fenugreek is recognized; asthma, rhinitis, sneezing, excessive tearing, bronchospasm, numbness of head, facial angioedema, wheezing, and toxic epidermal necrolysis have been documented in several case reports. Avoid if an allergy to any member of the Fabaceae family exists. Cross-reactivity to legumes is possible; consider allergy potential with chickpea, peanuts, soybeans, lentils, lupin, green peas,or coriander. 68, 69, 70, 79, 86, 90

An outbreak of Escherichia coli–related diarrhea in France and Germany in 2011 was associated with fenugreek sprouts.71, 72 Fenugreek sprouts have also been associated with some outbreaks of hemolytic–uremic syndrome caused by Shiga-toxin–producing Escherichia coli O104:H4 in Europe.80, 81

False diagnosis of maple syrup urine disease (see Pregnancy/Lactation) has been reported in several infants who were given fenugreek-containing herbal teas.53, 73, 74 The developing nervous system in children seems to be susceptible to fenugreek toxicity as demonstrated in both human and animal studies. Low to moderate doses have been shown to produce mild CNS stimulation in rats with higher doses producing twitches, tremors, painful stimuli, and generalized convulsions.90

Data collected between 2004 and 2013 from 8 US centers in the Drug-induced Liver Injury Network revealed that 15.5% (130) of hepatotoxicity cases were caused by herbals and dietary supplements, whereas 85% (709) of cases were related to prescription medications. Of the 130 cases of liver injury related to supplements, 65% were from non-bodybuilding supplements and occurred most often in Hispanics/Latinos compared with non-Hispanic whites and non-Hispanic blacks. Liver transplant was also more frequent with toxicity from non-bodybuilding supplements (13%) than with conventional medications (3%) (P<0.001). Overall, the proportion of severe liver injury cases was significantly higher for supplements than for conventional medications (P=0.02). Of the 217 supplement products implicated in liver injury, 175 had identifiable ingredients, of which fenugreek was among the 32 (18%) single-ingredient products.88


Based on animal studies, oral doses for humans should not exceed 350 mg/kg (21 g/60 kg) to prevent accidental overdose.90



This information relates to an herbal, vitamin, mineral or other dietary supplement. This product has not been reviewed by the FDA to determine whether it is safe or effective and is not subject to the quality standards and safety information collection standards that are applicable to most prescription drugs. This information should not be used to decide whether or not to take this product. This information does not endorse this product as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this product. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from your health care provider. You should talk with your health care provider for complete information about the risks and benefits of using this product.

This product may adversely interact with certain health and medical conditions, other prescription and over-the-counter drugs, foods, or other dietary supplements. This product may be unsafe when used before surgery or other medical procedures. It is important to fully inform your doctor about the herbal, vitamins, mineral or any other supplements you are taking before any kind of surgery or medical procedure. With the exception of certain products that are generally recognized as safe in normal quantities, including use of folic acid and prenatal vitamins during pregnancy, this product has not been sufficiently studied to determine whether it is safe to use during pregnancy or nursing or by persons younger than 2 years of age.

1. Trigonella L. USDA, NRCS. 3013. The PLANTS Database (, 21 November 2013). National Plant Data Team, Greensboro, NC 27401-4901 USA. Accessed February 24, 2014.
2. Ulbricht C, Basch E, Burke D, et al. Fenugreek (Trigonella foenum-graecum L. Leguminosae): an evidence-based systematic review by the natural standard research collaboration. J Herb Pharmacother. 2007;7(3-4):143-177.18928139
3. Madar Z, Stark AH. New legume sources as therapeutic agents. Br J Nutr. 2002;88(suppl 3):S287-S292.12498629
4. Sauvaire Y, Baccou JC. Extraction of diosgenin, (25R)-spirost-5-ene-3beta-ol; problems of the hydrolysis of the saponins. Lloydia. 1978;41:247-256.
5. Elujoba AA, Hardman R. Saponin-hydrolyzing enzymes from fenugreek seed. Fitoterapia. 1987;58:197-199.
6. Gangrade H, Mishra SH, Kanshal R. Antimicrobial activity of the oil and unsaponifiable matter of red rosette. Indian Drugs. 1979;16(7):147-148.
7. Chandel HS, Pathak AK, Tailang M. Standardization of some herbal antidiabetic drugs in polyherbal formulation. Pharmacognosy Res. 2011;3(1):49-56.21731396
8. Haber SL, Keonavong J. Fenugreek use in patients with diabetes mellitus. Am J Health Syst Pharm. 2013;70(14):1196, 1198, 1200, 1202-1203.23820455
9. Adamska M, Lutomski J. C-flavonoid glycosides in the seeds of Trigonella foenum graecum [in German]. Planta Med. 1971;20(3):224-229.5125489
10. Gupta RK, Jain DC, Thakur RS. Minor steroidal sapogenins from fenugreek seeds, Trigonella foenum-graecum. J Nat Prod. 1986;49:1153.
11. Karawya MS, Wassel GM, Baghdadi HH, Ammar NM. Mucilagenous contents of certain Egyptian plants. Planta Med. 1980;38:73-78.
12. Bae MJ, Shin HS, Choi DW, Shon DH. Antiallergic effect of Trigonella foenum-graecum L. extracts on allergic skin inflammation induced by trimellitic anhydride in BALB/c mice. J Ethnopharmacol. 2012;144(3):514-522.23036811
13. Mandegary A, Pournamdari M, Sharififar F, Pournourmohammadi S, Fardiar R, Shooli S. Alkaloid and flavonoid rich fractions of fenugreek seeds (Trigonella foenum-graecum L.) with antinociceptive and anti-inflammatory effects. Food Chem Toxicol. 2012;50(7):2503-2507.22542922
14. Suresh P, Kavitha ChN, Babu SM, Reddy VP, Latha AK. Effect of ethanol extract of Trigonella foenum graecum (Fenugreek) seeds on Freund's adjuvant-induced arthritis in albino rats. Inflammation. 2012;35(4):1314-1321.22395729
15. Varjas T, Nowrasteh G, Budán F, et al. The effect of fenugreek on the gene expression of arachidonic acid metabolizing enzymes. Phytother Res. 2011;25(2):221-227.20641053
16. Sindhu G, Ratheesh M, Shyni GL, Nambisan B, Helen A. Anti-inflammatory and antioxidative effects of mucilage of Trigonella foenum graecum (Fenugreek) on adjuvant induced arthritic rats. Int Immunopharmacol. 2012;12(1):205-211.22155102
17. Yadav UC, Baquer NZ. Pharmacological effects of Trigonella foenum-graecum L. in health and disease. Pharm Biol. 2014;52(2):243-254.24102093
18. Kaviarasan S, Vijayalakshmi K, Anuradha CV. Polyphenol-rich extract of fenugreek seeds protect erythrocytes from oxidative damage. Plant Foods Hum Nutr. 2004;59:143-147.15678722
19. Thirunavukkarasu V, Anuradha CV, Viswanathan P. Protective effect of fenugreek (Trigonella foenum graecum) seeds in experimental ethanol toxicity. Phytother Res. 2003;17(7):737-743.12916070
20. Sakr SA, Mahran HA, Abo-El-Yazid SM. Effect of fenugreek seeds extract on cyclophosphamide-induced histomorphometrical, ultrastructural and biochemical changes in testes of albino mice. Toxicol Ind Health. 2012;28(3):276-288.21949087
21. Belaïd-Nouira Y, Bakhta H, Bouaziz M, Flehi-Slim I, Haouas Z, Ben Cheikh H. Study of lipid profile and parieto-temporal lipid peroxidation in AlCl3 mediated neurotoxicity. Modulatory effect of fenugreek seeds. Lipids Health Dis. 2012;11:16.22280491
22. Navayath S, Thiyagarajan D. Fenugreek supplementation imparts erythrocyte resistance to cypermethrin induced oxidative changes in vivo. J Complement Integr Med. 2011;8.22754936
23. Murugesan M, Revathi R, Manju V. Cardioprotective effect of fenugreek on isoproterenol-induced myocardial infarction in rats. Indian J Pharmacol. 2011;43(5):516-519.22021992
24. Chatterjee S, Kumar M, Kumar A. Chemomodulatory effect of Trigonella foenum graecum (L.) seed extract on two stage mouse skin carcinogenesis. Toxicol Int. 2012;19(3):287-294.23293468
25. Al-Daghri NM, Alokail MS, Alkharfy KM, et al. Fenugreek extract as an inducer of cellular death via autophagy in human T lymphoma Jurkat cells. BMC Complement Altern Med. 2012;12:202.23110539
26. Al-Oqail MM, Farshori NN, Al-Sheddi ES, Musarrat J, Al-Khedhairy AA, Siddiqui MA. In vitro cytotoxic activity of seed oil of fenugreek against various cancer cell lines. Asian Pac J Cancer Prev. 2013;14(3):1829-1832.23679282
27. Chen PS, Shih YW, Huang HC, Cheng HW. Diosgenin, a steroidal saponin, inhibits migration and invasion of human prostate cancer PC-3 cells by reducing matrix metalloproteinases expression. PLoS One. 2011;6(5):e20164.21629786
28. Das S, Dey KK, Dey G, et al. Antineoplastic and apoptotic potential of traditional medicines thymoquinone and diosgenin in squamous cell carcinoma. PLoS One. 2012;7(10):e46641.23077516
29. Sur P, Das M, Gomes A, et al. Trigonella foenum graecum (fenugreek) seed extract as an antineoplastic agent. Phytother Res. 2001;15(3):257-259.11351364
30. Jäger AK, Gauguin B, Andersen J, Adsersen A, Gudiksen L. Screening of plants used in Danish folk medicine to treat depression and anxiety for affinity to the serotonin transporter and inhibition of MAO-A. J Ethnopharmacol. 2013;145(3):822-825.23266274
31. Morani AS, Bodhankar SL, Mohan V, Thakurdesai PA. Ameliorative effects of standardized extract from Trigonella foenum-graecum L. seeds on painful peripheral neuropathy in rats. Asian Pac J Trop Med. 2012;5(5):385-390.22546656
32. Gaur V, Bodhankar SL, Mohan V, Thakurdesai PA. Neurobehavioral assessment of hydroalcoholic extract of Trigonella foenum-graecum seeds in rodent models of Parkinson's disease. Pharm Biol. 2013;51(5):550-557.23368940
33. Nathan J, Panjwani S, Mohan V, Joshi V, Thakurdesai PA. Efficacy and safety of standardized extract of Trigonella foenum-graecum L seeds as an adjuvant to L-dopa in the management of patients with Parkinson's disease. Phytother Res. 2013;28(2):172-178.23512705
34. Gupta A, Gupta R, Lal B. Effect of Trigonella foenum graecum (fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus: a double blind placebo controlled study. J Assoc Physicians India. 2001;49:1057-1061.11868855
35. Roberts KT. The potential of fenugreek (Trigonella foenum-graecum) as a functional food and nutraceutical and its effects on glycemia and lipidemia. J Med Food. 2011;14(12):1485-1489.21861724
36. Al-Habori M, Raman A. Antidiabetic and hypocholesterolaemic effects of fenugreek. Phytother Res. 1998;12(4):233-242.
37. Baquer NZ, Kumar P, Taha A, Kale RK, Cowsik SM, McLean P. Metabolic and molecular action of Trigonella foenum-graecum (fenugreek) and trace metals in experimental diabetic tissues. J Biosci. 2011;36(2):383-396.21654091
38. Bera TK, Ali KM, Jana K, Ghosh A, Ghosh D. Protective effect of aqueous extract of seed of Psoralea corylifolia (somraji) and seed of Trigonella foenum-graecum L. (methi) in streptozotocin-induced diabetic rat: a comparative evaluation. Pharmacognosy Res. 2013;5(4):277-285.24174822
39. Haeri MR, Limaki HK, White CJ, White KN. Non-insulin dependent anti-diabetic activity of (2S, 3R, 4S) 4-hydroxyisoleucine of fenugreek (Trigonella foenum graecum) in streptozotocin-induced type I diabetic rats. Phytomedicine. 2012;19(7):571-574.22397995
40. Hamza N, Berke B, Cheze C, et al. Preventive and curative effect of Trigonella foenum-graecum L. seeds in C57BL/6J models of type 2 diabetes induced by high-fat diet. J Ethnopharmacol. 2012;142(2):516-522.22633967
41. Haritha C, Reddy AG, Reddy YR, et al. Evaluation of protective action of fenugreek, insulin and glimepiride and their combination in diabetic Sprague Dawley rats. J Nat Sci Biol Med. 2013;4(1):207-212.23633864
42. Hannan JM, Rokeya B, Faruque O, et al. Effect of soluble dietary fibre fraction of Trigonella foenum graecum on glycemic, insulinemic, lipidemic and platelet aggregation status of Type 2 diabetic model rats. J Ethnopharmacol. 2003;88(1):73-77.12902054
43. Lu FR, Shen L, Qin Y, Gao L, Li H, Dai Y. Clinical observation on Trigonella foenum-graecum L. total saponins in combination with sulfonylureas in the treatment of type 2 diabetes mellitus. Chin J Integr Med. 2008;14(1):56-60.18219452
44. Losso JN, Holliday DL, Finley JW, et al. Fenugreek bread: a treatment for diabetes mellitus. J Med Food. 2009;12(5):1046-1049.19857068
45. Belguith-Hadriche O, Bouaziz M, Jamoussi K, Simmonds MS, El Feki A, Makni-Ayedi F. Comparative study on hypocholesterolemic and antioxidant activities of various extracts of fenugreek seeds. Food Chem. 2013;138(2-3):1448-1453.23411266
46. Chaturvedi U, Shrivastava A, Bhadauria S, Saxena JK, Bhatia G. A mechanism-based pharmacological evaluation of efficacy of Trigonella foenum graecum (fenugreek) seeds in regulation of dyslipidemia and oxidative stress in hyperlipidemic rats. J Cardiovasc Pharmacol. 2013;61(6):505-512.23429594
47. Thompson Coon JS, Ernst E. Herbs for serum cholesterol reduction: a systematic view. J Fam Pract. 2003;52(6):468-478.12791229
48. Sergere JC, inventor. Fenugreek extract for treating human and animal diseases involving flagellate parasites. U.S. patent application 20110123656. May 26, 2011.
49. DiSilvestro RA, Verbruggen MA, Offutt EJ. Anti-heartburn effects of a fenugreek fiber product. Phytother Res. 2011;25(1):88-91.20623611
50. Pandian RS, Anuradha CV, Viswanathan P. Gastroprotective effect of fenugreek seeds (Trigonella foenum graecum) on experimental gastric ulcer in rats. J Ethnopharmacol. 2002;81(3):393-397.12127242
51. Vats V, Yadav SP, Biswas NR, Grover JK. Anti-cataract activity of Pterocarpus marsupium bark and Trigonella foenum-graecum seeds extract in alloxan diabetic rats. J Ethnopharmacol. 2004;93(2-3):289-294.15234767
52. Khalki L, Bennis M, Sokar Z, Ba-M'hamed S. The developmental neurobehavioral effects of fenugreek seeds on prenatally exposed mice. J Ethnopharmacol. 2012;139(2):672-677.22178172
53. Korman SH, Cohen E, Preminger A. Pseudo-maple syrup urine disease due to maternal prenatal ingestion of fenugreek. J Paediatr Child Health. 2001;37(4):403-404.11532065
54. Forinash AB, Yancey AM, Barnes KN, Myles TD. The use of galactogogues in the breastfeeding mother. Ann Pharmacother. 2012;46(10):1392-1404.23012383
55. Mortel M, Mehta SD. Systematic review of the efficacy of herbal galactogogues. J Hum Lact. 2013;29(2):154-162.23468043
56. Mousa SA. Antithrombotic effects of naturally derived products on coagulation and platelet function. Methods Mol Biol. 2010;663:229-240.20617421
57. Stanger MJ, Thompson LA, Young AJ, Lieberman HR. Anticoagulant activity of select dietary supplements. Nutr Rev. 2012;70(2):107-117.22300597
58. Spolarich AE, Andrews L. An examination of the bleeding complications associated with herbal supplements, antiplatelet and anticoagulant medications. J Dent Hyg. 2007;81(3):67.17908423
59. Ulbricht C, Chao W, Costa D, Rusie-Seamon E, Weissner W, Woods J. Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Curr Drug Metab. 2008;9(10):1063-1120.19075623
60. Hui H, Tang G, Go VL. Hypoglycemic herbs and their action mechanisms. Chin Med. 2009;4:11.1953223
61. Lambert JP, Cormier J. Potential interaction between warfarin and boldo-fenugreek. Pharmacotherapy. 2001;21(4):509-512.11310527
62. Izzo AA, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol. 2005;98(1):1-14.15676159
63. Teng CM, Hsueh CM, Chang YL, Ko FN, Lee SS, Liu KC. Antiplatelet effects of some aporphine and phenanthrene alkaloids in rabbits and man. J Pharm Pharmacol. 1997;49(7):706-711.9255715
64. FDA. Food Additive Status List. Updated March 21, 2013. Accessed November 20, 2013.
65. Posadzki P, Watson LK, Ernst E. Adverse effects of herbal medicines: an overview of systematic reviews. Clin Med. 2013;13(1):7-12.23472485
66. Panda S, Tahiliani P, Kar A. Inhibition of triiodothyronine production by fenugreek seed extract in mice and rats. Pharmacol Res. 1999;40(5):405-409.10527654
67. Tahiliani P, Kar A. The combined effects of trigonella and allium extracts in the regulation of hyperthyroidism in rats. Phytomedicine. 2003;10(8):665-668.14692727
68. Ohnuma N, Yamaguchi E, Kawakami Y. Anaphylaxis to curry powder. Allergy. 1998;53(4):452-454.9574894
69. Namork E, Fæste CK, Stensby BA, Egaas E, Løvik M. Severe allergic reactions to food in Norway: a ten year survey of cases reported to the food allergy register. Int J Environ Res Public Health. 2011;8(8):3144-3155.21909296
70. Vinje NE, Namork E, Løvik M. Anaphylactic reactions in mice with fenugreek allergy. Scand J Immunol. 2011;74(4):342-353.21645030
71. King LA, Nogareda F, Weill FX, et al. Outbreak of Shiga toxin-producing Escherichia coli O104:H4 associated with organic fenugreek sprouts, France, June 2011. Clin Infect Dis. 2012;54(11):1588-1594.22460976
72. Morgan KL. Infection, illness, and fenugreek seeds: was illness a good enough proxy for infection in the 2011 outbreak of Shiga toxin-producing Escherichia coli O104:H4 in France? Clin Infect Dis. 2013;56(7):1055-1056.23223592
73. Sewell A, Mosandl A, Böhles H. False diagnosis of maple syrup urine disease owing to ingestion of herbal tea. N Engl J Med. 1999;341(10):769.10475807
74. Bartley GB, Hilty MD, Andreson BD, Clairmont AC, Maschke SP. "Maple-syrup" urine odor due to fenugreek ingestion. N Engl J Med. 1981;305(8):467.7254294
75. Shabbeer S, Sobolewski M, Anchoori RK, et al. Fenugreek: a naturally occurring edible spice as an anticancer agent. Cancer Biol Ther. 2009;8(3):272-278.19197146
76. Mathern JR, Raatz SK, Thomas W, Slavin JL. Effect of fenugreek fiber on satiety, blood glucose and insulin response and energy intake in obese subjects. Phytother Res. 2009;23(11):1543-1548.19353539
77. DiSilvestro RA, Verbruggen MA, Offutt EJ. Anti-heartburn effects of a fenugreek fiber product. Phytother Res. 2011;25(1):88-91.20623611
78. Li SW, Siu CW, Lau CP, Tse HF. Effect of herbal consumption on time in therapeutic range of warfarin therapy in patients with atrial fibrillation. J Cardiovasc Pharmacol. 2011;58(1):87-90.21558883
79. Faeste CK, Namork E, Lindvik H. Allergenicity and antigenicity of fenugreek (Trigonella foenum-graecum) proteins in foods. J Allergy Clin Immunol. 2009;123(1):187-194.18930518
80. King LA, Nogareda F, Weill FX, et al. Outbreak of Shiga toxin-producing Escherichia coli O104:H4 associated with organic fenugreek sprouts, France, June 2011. Clin Infect Dis. 2012;54(11):1588-1594.22460976
81. Frank C, Werber D, Cramer JP, et al. Epidemic profile of Shigatoxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med. 2011;365:1771–1780.22029753
82. Nathan J, Panjwani S, Mohan V, Joshi V, Thakurdesai PA. Efficacy and safety of standardized extract of Trigonella foenum-graecum L seeds as an adjuvant to L-Dopa in the management of patients with Parkinson's disease. Phytother Res. 2014;28(2):172-178.23512705
83. Neelakantan N, Narayanan M, de Souza RJ, van Dam RM. Effect of fenugreek (Trigonella foenum-graecum L.) intake on glycemia: a meta-analysis of clinical trials. Nutr J. 2014;13:7.24438170
84. Pattanittum P, Kunyanone N, Brown J, et al. Dietary supplements for dysmenorrhoea. Cochrane Database Syst Rev. 2016;3:CD002124.27000311
85. Zaidi SF, Muhammad JS, Shahryar S, et al. Anti-inflammatory and cytoprotective effects of selected Pakistani medicinal plants in Helicobacter pylori-infected gastric epithelial cells. J Ethnopharmacol. 2012;141(1):403-410.22433535
86. Vinje NE, Namork E, Løvik M. Cross-allergic reactions to legumes in lupin and fenugreek-sensitized mice. Scand J Immunol. 2012;76(4):387-397.
87. Shamshad Begum S, Jayalakshmi HK, Vidyavathi HG, et al. A novel extract of fenugreek husk (FenuSMART™) alleviates postmenopausal symptoms and helps to establish the hormonal balance; a randomized, double-blind, placebo-controlled study. Phytother Res. 2016 Jul 13. [epub ahead of print]
88. Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the U.S. drug-induced liver injury network. Hepatology. 2014;60(4):1399-1408.25043597
89. Gong J, Fang K, Dong H, Wang D, Hu M, Lu F. Effect of fenugreek on hyperglycaemia and hyperlipidemia in diabetes and prediabetes: a meta-analysis. J Ethnopharmacol. 2016;194:260-268.27496582
90. Ouzir M, Bairi KE, Amzazi S. Toxicological properties of fenugreek (Trigonella foenum graecum). Food Chem Toxicol. 2016;96:145-154.27498339
91. Philips CA, Augustine P. Rare cause of isolated severe coagulation failure in cirrhosis: traditional healing with fenugreek. BMJ Case Rep. 2018;2018:bcr-2017-223479.29330279
92. Khan TM, Wu DB, Dolzhenko AV. Effectiveness of fenugreek as a galactagogue: a network meta-analysis. Phytother Res. 2018;32(3):402-412.29193352
93. Dennehy C, Tsourounis C, Bui L, King TL. The use of herbs by California midwives. J Obstet Gynecol Neonatal Nurs. 2010;39(6):684-693.21044150
94. Doolabh K, Finnegan D, Pehlivan N, Farrand S. Oral fenugreek seed consumption and serotonin syndrome. Aust N Z J Psychiatry. 2019;53(12):1225.31379190

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.